Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Bypassing the blood-brian barrier using established skull base reconstruction techniques.

Miyake MM, Bleier BS.

World J Otorhinolaryngol Head Neck Surg. 2015 Oct 23;1(1):11-16. doi: 10.1016/j.wjorl.2015.09.001. eCollection 2015 Sep. Review.

2.

The Growth Inhibitory Potential and Antimetastatic Effect of Camel Urine on Breast Cancer Cells In Vitro and In Vivo.

Romli F, Abu N, Khorshid FA, Syed Najmuddin SUF, Keong YS, Mohamad NE, Hamid M, Alitheen NB, Nik Abd Rahman NMA.

Integr Cancer Ther. 2017 Dec;16(4):540-555. doi: 10.1177/1534735416656051. Epub 2016 Jun 23.

3.

Autoimmunity as a double agent in tumor killing and cancer promotion.

Toomer KH, Chen Z.

Front Immunol. 2014 Mar 18;5:116. doi: 10.3389/fimmu.2014.00116. eCollection 2014. Review.

4.

Impacts of blood-brain barrier in drug delivery and targeting of brain tumors.

Omidi Y, Barar J.

Bioimpacts. 2012;2(1):5-22. doi: 10.5681/bi.2012.002. Epub 2012 Feb 2.

5.

Toxin-based targeted therapy for malignant brain tumors.

Chandramohan V, Sampson JH, Pastan I, Bigner DD.

Clin Dev Immunol. 2012;2012:480429. doi: 10.1155/2012/480429. Epub 2012 Feb 9. Review.

6.

Targeted toxins in brain tumor therapy.

Li YM, Hall WA.

Toxins (Basel). 2010 Nov;2(11):2645-62. doi: 10.3390/toxins2112645. Epub 2010 Nov 1. Review.

7.

Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors.

Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, Saltzman WM.

Drug Deliv Transl Res. 2011 Feb 1;1(1):34-42. doi: 10.1007/s13346-010-0001-3.

8.
9.

Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring.

Mardor Y, Last D, Daniels D, Shneor R, Maier SE, Nass D, Ram Z.

J Pharmacol Exp Ther. 2009 Aug;330(2):520-5. doi: 10.1124/jpet.109.154401. Epub 2009 May 28.

10.

Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J.

Neurosurg Rev. 2008 Apr;31(2):141-55; discussion 155. doi: 10.1007/s10143-008-0121-0. Epub 2008 Feb 8. Review.

11.

Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting.

Rosca EV, Stukel JM, Gillies RJ, Vagner J, Caplan MR.

Biomacromolecules. 2007 Dec;8(12):3830-5. Epub 2007 Nov 27.

12.

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, Tighiouart M, Van Meir EG.

Cancer Res. 2007 Jul 15;67(14):6872-81. Erratum in: Cancer Res. 2007 Sep 1;67(17):8422-3.

Supplemental Content

Support Center